Immunotherapy Flashcards

Question

What is the generic of name of Imjudo?

Answer 1

The generic name of this brand name drug is: - Tremelimumab

Answer 2

This drug in the following class: - Immunotherapy - Anti-PD-1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 3

This drug in the following class: - Immunotherapy - Anti-PD-1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 4

This drug in the following class: - Immunotherapy - Anti-PD-1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 5

This drug in the following class: - Immunotherapy - Anti-PD-1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 6

This drug in the following class: - Immunotherapy - Anti-PD-1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 7

This drug in the following class: - Immunotherapy - Anti-PD-1 + Anti-LAG-3 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 8

This drug in the following class: - Immunotherapy - Anti-PD-L1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 9

This drug in the following class: - Immunotherapy - Anti-PD-L1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 10

This drug in the following class: - Immunotherapy - Anti-PD-L1 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 11

This drug in the following class: - Immunotherapy - Anti-CTLA4 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 12

This drug in the following class: - Immunotherapy - Anti-CTLA4 This drug's MOA is as follows: - Immune checkpoint inhibitors remove inhibitory signals of T-cell activation, which enables tumor- reactive T-cells to overcome regulatory mechanisms and mount an effective antitumor response.

Answer 13

The notable/common monitoring parameters for this drug class are: - TSH/T4 at baseline and every 4-6 weeks - LFTs (AST, ALT, and bilirubin) at baseline and periodically during treatment - Serum creatinine at baseline and periodically during treatment

Answer 14

The emetic potential of this drug class is: - Minimal

Answer 15

The emetic potential of this drug class is: - Minimal

Answer 16

The emetic potential of this drug class is: - Minimal

Answer 17

The extravasation risk and management strategies for this drug class are as follows: - None, N/A

Answer 18

The extravasation risk and management strategies for this drug class are as follows: - None, N/A

Answer 19

The extravasation risk and management strategies for this drug class are as follows: - None, N/A

Answer 20

The notable/common ADRs of this drug class are: - Immune related adverse events (irAEs) - These irAEs can affect any organ/tissue in the body (skin, GI tract lungs, liver, thyroid, etc.). - The most common irAEs with these agents are rash, pruritus, diarrhea, colitis, elevated liver enzymes/ bilirubin, hepatitis, hypophysitis, and hypothyroidism.

Answer 21

The strategy and rationale for management of this condition caused by this drug are: - Patients should be educated on the mechanism of action of immunotherapy and when a new side effect occurs, there should be a high suspicion for it being treatment-related. - Though treatment interruption may be needed for some irAEs depending on severity, dose adjustments are not recommended after restarting therapy following toxicity. - Toxicity Management (except hypothyroidism): - Grade 1 toxicity: Continue immunotherapy with close monitoring - Grade 2 toxicity: Hold immunotherapy (may resume when toxicity< grade 1). Prednisone 0.5-1 mg/kg/day or equivalent may be administered - Grade 3 toxicity: Hold immunotherapy (may resume when toxicity< grade 1). Start prednisone 1-2 mg/ kg/ day or methylprednisolone IV 1-2 mg/kg/day with taper over > 4-6 weeks. If no improvement after 48-72 hours, then consider infliximab - Grade 4 toxicity: Permanently discontinue immunotherapy

Answer 22

The strategy and rationale for management of this condition caused by this drug are: - Thyroid supplementation in symptomatic patients with TSH levels> 10 mIU/L, monitor every 6-8 weeks while titrating

Answer 23

The half-life of the this drug is described as follows: - The typical half-life of these agents ranges from 15-27 days - This leads to a longer time to tumor response compared to traditional cytotoxic chemotherapy

Answer 24

The clinical pearls of this drug class are as follows: - Drug interactions - As steroids are known to reduce the immune response (and are used to treat immune related adverse events), they may diminish the therapeutic effect of Immune Checkpoint Inhibitors. - Carefully consider the need for corticosteroids during the initiation of Immune Checkpoint inhibitor therapy. - Generally, doses of a prednisone-equivalent of 10 mg or less per day are permitted. - Combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) results in enhanced T-cell function that is greater than that of either antibody alone, resulting in improved anti-tumor responses in metastatic melanoma and advanced renal cell carcinoma.

Answer 25

The clinical pearls of this drug are as follows: - It was one of the first oncology drugs approved for a specific genetic marker (tumors with high microsatellite instability) regardless of cancer type or tissue diagnosis. - This means that any patient whose tumor is MSI high is eligible to receive this drug.

Immunotherapy Flashcards

(49 cards)